亚辉龙 (688575)
Shenzhen YHLO Biotech Co., Ltd.
K-Line Chart
No K-line data available
Company NameShenzhen YHLO Biotech Co., Ltd.
Listing Date2021-05-17
Issue Price14.8RMB
Registered Capital57042.6810k RMB
Legal RepresentativeSong Yongbo
Registered AddressBuilding 1, YHLO Biotech Factory Area, Baolong 2nd Road, Baolong Street, Longgang District, Shenzhen, Guangdong Province
IndustryMedical Devices
Main BusinessResearch, development, production, and sales of in vitro diagnostic instruments and supporting reagents primarily based on chemiluminescence immunoassay, as well as the distribution business of some non-self-produced medical device products.
Company ProfileSince its establishment, Shenzhen YHLO Biotech Co., Ltd. has set up a European R&D center, keeping pace with European technology. It has established R&D and production quality systems based on EU quality standards, passed ISO9001 and ISO13485 quality system certifications, and obtained review and certification from TüV-SUD, one of the world's most stringent IVD certification bodies. YHLO has established technical strategic partnerships with several renowned high-tech enterprises, universities, and research institutions in the United States, Germany, Italy, South Korea, and Taiwan, China. The company aims to address global clinical needs by developing medical device products with independent intellectual property rights. Based on technological platforms such as acridinium ester magnetic particle chemiluminescence, novel ship-type enzyme immunoassay, enzyme-linked immunosorbent assay, and immunoblotting, it meticulously develops required instruments and provides supporting reagents and services for various fields related to human health worldwide, such as autoimmune diseases, infections, reproductive health, and diabetes.
Stock Details
1. Key Indicators
- Total Shares(W): 57042.68
- Circulating A-Shares(W): 57042.68
- Earnings Per Share(RMB): 0.1100
- Net Assets Per Share(RMB): 4.7383
- Operating Revenue(W RMB): 128671.14
- Total Profit(W RMB): 6447.77
- **Net Profit Attributable to Parent(W RMB) **: 6042.09
- Net Profit Growth Rate(%): -72.36
- Weighted Return on Equity(%): 2.1700
- Operating Cash Flow Per Share(RMB): 0.1140
- Undistributed Profit Per Share(RMB): 2.4611
- Capital Reserve Per Share(RMB): 0.8529
2. Main Business
The main business covers:
- Research, production, and sales of in-vitro diagnostic instruments and supporting reagents primarily based on chemiluminescence immunoassay
- Agency sales business for some non-self-produced medical device products
3. Company Basic Information
- Company Name: Shenzhen YHLO Biotech Co., Ltd.
- Listing Date: 2021-05-17
- Industry: Pharmaceutical Manufacturing
- Address: Building 1, YHLO Biotech Factory Area, Baolong 2nd Road, Baolong Street, Longgang District, Shenzhen City, Guangdong Province
- Website: https://www.szyhlo.com/
- Company Profile: The company was established in 2015 and transformed into a joint stock company, focusing on the research, production, and sales of in-vitro diagnostic instruments and supporting reagents primarily based on chemiluminescence immunoassay.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shenzhen Puhui Zhonglian Industrial Investment Co., Ltd. | General Legal Person | 4645.10 | 8.14 |
| 2 | Shenzhen Yingfu Huizhi Private Securities Fund Management Co., Ltd. - Yingfu Zengxin Yinhe Yixing No. 5 Private Securities Investment Fund | Private Securities Investment Fund | 1523.91 | 2.67 |
| 3 | Jiaxing Ruiyao Venture Capital Partnership (Limited Partnership) | General Legal Person | 1278.08 | 2.24 |
| 4 | Hainan Shuofeng Private Fund Management Partnership (Limited Partnership) - Shuofeng Changjiang No. 3 Private Securities Investment Fund | Private Securities Investment Fund | 1124.71 | 1.97 |
| 5 | Ningbo Pengrui Enterprise Management Partnership (Limited Partnership) | General Legal Person | 1055.76 | 1.85 |
| 6 | Huabao CSI Medical ETF | Fund | 965.16 | 1.69 |
| 7 | Shanghai Liyi Investment Management Partnership (Limited Partnership) - Suzhou Lirun Equity Investment Center (Limited Partnership) | General Legal Person | 605.49 | 1.06 |
| 8 | Penghua SSE STAR 100 ETF联接基金A类 | Fund | 0.14 | 0.00 |
5. Concept Sectors
- Gene Concept
- Assisted Reproduction
- Hepatitis Concept
- DeepSeek
- Margin Trading & Securities Lending
- Intensive Research
- Heavy Private Placement Holdings
- SSE 380
- STAR Market Biotech
- STAR 100
Remarks
- Data update date: 2025-11-07
- Data source: Public Market Information